CURRICULUM VITAE 

Hiroharu Yamashita, MD, PhD 

PERSONAL INFORMATION  

Date of Birth: November 17, 1973  

Place of Birth: Shimonoseki, Yamaguchi, Japan 

Citizenship: Japan 

Home address: 3-26-3-305, Tsukishima, Chuo-ku, Tokyo 104-0052 

Japan  

Professional address: Department of Digestive Surgery, Nihon University School of Medicine 

1-6, Kanda-Surugadai, Chiyoda-ku, Tokyo 101-8309 Japan 

Tel: +81-3-3293-1711  

  E-mail: hyamashi-tky@umin.net 

EDUCATION/POST GRADUATE TRAINING  

College/University: 

1992-1998 MD, Faculty of Medicine, The University of Tokyo 

2003-2007 PhD, Department of Surgical Oncology, Graduate School of Medicine,  

The University of Tokyo 

Residency:  

1998-1999 Resident in Surgery, The University of Tokyo Hospital, Tokyo, Japan 

Fellowship: 

1999-2002 Fellow in Surgery, Kanto Rosai Hospital, Kawasaki, Kanagawa, Japan 

2002-2003 Fellow in Surgery, The University of Tokyo Hospital, Tokyo, Japan 

MEDICAL LICENSURE  

Full Medical License (Japan) #397010 

BOARD CERTIFICATION  

Dec 2006 Board Certified Surgeon of Japan Surgical Society 

Jan 2009 Board Cetified Gastroenterologist of The Japanese Society of Gastroenterology 

Jan 2010 Board Certified Surgeon in Gastroenterology of The Japanese Society of Gastroenterological Surgery 

PRESENT POSITION OR ACADEMIC RANK  

Professor, Department of Digestive Surgery, Nihon University School of Medicine 

PREVIOUS PROFESSIONAL POSITIONS AND APPOINTMENTS  

2007-2009 Staff Surgeon, Ibaraki Prefectural Central Hospital and Cancer Center 

2009-2010 Chief Resident, Gastric Surgery Division, National Cancer Center Hospital 

2010-2012 Assistant Professor, Department of Surgical Oncology,  

Graduate School of Medicine, The University of Tokyo 

2012-2013 Assistant Professor, Department of Gastrointestinal Surgery,  

Graduate School of Medicine, The University of Tokyo 

2013-2020 Lecturer, Department of Gastrointestinal Surgery,  

Graduate School of Medicine, The University of Tokyo 

PUBLICATIONS (as a first author only) 

1.Yamashita H, Otani T, Shioiri T, Takayama T, Kakiuchi C, Todani T, Makuuchi M. Smallest Todani’s type II choledochal cyst. Dig Liver Dis. 2003;35:498-502. 

2.Yamashita H, Kitayama J, Nagawa H. Hyperfibrinogenemia is a useful predictor for lymphatic metastasis in human gastric cancer. Jpn J Clin Oncol 2005;35:595-600. 

3.Yamashita H, Ishimaru M, Yamaguchi H, Yamauchi H, Sugiura A, Kitayama J, Nagawa H. Massive postoperative polyuria following total gastrectomy for gastric cancer. J Anesth 2006;20:36-9. 

4.Yamashita H, Kitayama J, Ishigami H, Yamaguchi H, Souma D, Nagano R, Nagawa H. Multiple gastric tube carcinomas after curative oesophagectomy. Dig Liver Dis 2006;38:214-5.

5.Yamashita H, Kitayama J, Kanno N, Yatomi Y, Nagawa H. Hyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer. BMC cancer 2006;6:147. 

6.Yamashita H, Kitayama J, Shida D, Ishikawa M, Hama K, Aoki J, Arai H, Nagawa H. Differential expression of lysophosphatidic acid receptor-2 in intestinal and diffuse type gastric cancer. J Surg Oncol 2006;93:30-5. 

7.Yamashita H, Kitayama J, Shida D, Yamaguchi H, Mori K, Osada M, Aoki S, Yatomi Y, Takuwa Y, Nagawa H. Sphingosine 1-phosphate receptor expression profile in human gastric cancer cells: differential regulation on the migration and proliferation. J Surg Res 2006;130:80-7. 

8.Yamashita H, Kitayama J, Ishigami H, Yamada J, Miyato H, Kaisaki S, Nagawa H. Endoscopic instillation of indigo carmine dye with acetic acid enables the visualization of distinct margin of superficial gastric lesion; Usefulness in endoscopic treatment and diagnosis of gastric cancer. Dig Liver Dis 2007;39:389-91. 

9.Yamashita H, Kitayama J, Ishikawa M, Nagawa H. Tissue factor expression is a clinical indicator of lymphatic metastasis and poor prognosis in gastric cancer with intestinal phenotype. J Surg Oncol 2007;95:324-31. 

10.Yamashita H, Yoshimi F, Mori K, Mochizuki Y, Nagai H, Ikeda H, Shioyama Y, Yamada K. Replacement of the common hepatic artery by the left gastric artery: a rare variant in gastric cancer surgery. Eur J Surg Oncol 2008;34:943-4. 

11.Yamashita H, Shinozaki H, Otani T. Generation of trypsinogen activation peptide activity in rat isolated pancreatic acini under bombesin stimulation. Pancreas 2008;36:208-9. 

12.Yamashita H, Kitayama J, Nagawa H. Chromoendoscopy with indigo carmine dye added to acetic acid in the diagnosis of gastric neoplasia. Gastrointest Endosc 2009;69:1407-8. 

13.Yamashita H, Kitayama J, Taguri M, Nagawa H. Effect of preoperative hyperfibrinogenemia on recurrence of colorectal cancer without a systemic inflammatory response. World J Surg 2009;33:1298-305. 

14.Yamashita H, Yoshimi F, Sato M, Saito H, Iijima T, Nagai H. A case of salvage esophagectomy for local failure after definitive chemoradiation therapy: fluorodeoxyglucose positron emission tomography (FDG-PET) failed to demonstrate the local lesion and a positive lymph node. Esophagus 2009;6:210-213. 

15.Yamashita H, Hata K, Yamaguchi H, Tsurita G, Wake K, Watanabe S, Taki M, Ueno S, Nagawa H. Short-term exposure to a 1439-MHz TDMA signal exerts no estrogenic effect in rats. Bioelectromagnetics 2010;31:573-5. 

16.Yamashita H, Katai H. Systemic inflammatory response in gastric cancer. World J Surg 2010;34:2399-400. 

17.Yamashita H, Katai H, Morita S, Saka M, Taniguchi H, Fukagawa T. Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Ann Surg 2011;254:274-80.

18. Yamashita H, Katai H. Adenocarcinoma of the esophagogastric junction be classified as esophageal Cancer? Limited to Siewert type II, yes. Ann Surg 2015;261:e

 19. Yamashita H, Seto Y. Is the transthoracic approach no longer a viable option for Siewert type II esophagogastric junction carcinoma? Translational Gastroenterology and Hepatology 2016;1:14

 20. Yamashita H, Yagi K, Seto Y. How should we define the no. 3b lesser curvature lymph node? Gastric Cancer. 2017;20:558-559

 21.Yamashita H, Seto Y, Sano T, Makuuchi H, Ando N, Sasako M; Japanese Gastric Cancer Association and the Japan Esophageal Society. Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer. 2017 Mar;20(Suppl 1):69-83

 22. Yamashita H, Deng J, Liang H, Seto Y. Re-evaluating the prognostic validity of the negative to positive lymph node ratio in node-positive gastric cancer patients. Surgery. 2017;161:1588-1596

 23. Yamashita H, Deng J, Liang H, Seto Y. Reply to: LODDS or negative to positive lymph nodes ratio? Surgery. 2017;162(5):1190-1191